Immunoradiotherapy for NSCLC: mechanisms, clinical outcomes, and future directions

• He Weishan ^[1] ; Zheng Donglin ^[2] ; Deng Guangmei ^[1] ; Liu Wenya ^[1] ; Wu Fasheng ^[2] ; Chen Jibing ^[2]
  1. [1] Graduate School, Guangxi University of Chinese Medicine, Nanning, Guangxi, China
  2. [2] Ruikang Hospital, Guangxi University of Chinese Medicine, Nanning, Guangxi, China
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 5, 2024, págs. 1063-1076
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Non-small-cell lung cancer (NSCLC) has an extremely low 5-year survival rate, with the only effective treatment being immunoradiotherapy (iRT). Here, we review the progress of clinical research on iRT for non-small-cell lung cancer (NSCLC) over 2018–2023, as well as the future directions. We first discuss the synergistic mechanisms of iRT, reflected in three aspects: immune regulation of RT, RT-activated immune-related pathways, and RT-related immune sensitization. iRT may include either external-beam or stereotactic-body RT combined with either immune checkpoint inhibitors (e.g., immunoglobulins against immune programmed cell death (PD) 1/PD ligand 1 or CD8+ T lymphocyte antigen 4) or traditional Chinese medicine drugs. Regarding clinical effectiveness and safety, iRT increases overall and progression-free survival and tumor control rate among patients with NSCLC but without a considerable increase in toxicity risk. We finally discuss iRT challenges and future directions reported over 2018–2023.